Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-10-29 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
第三届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 20th meeting of the third board of directors of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes details about the meeting date, attendees, and voting results on several agenda items. The key agenda items include approval of the 2024 third quarter report, nomination and election of the fourth board of directors and independent directors, and the proposal to convene the 2024 second extraordinary general meeting. The document references that the full 2024 third quarter report and other related announcements are disclosed on the Beijing Stock Exchange website, indicating this document itself is not the full quarterly report but a board meeting resolution announcement. The main focus is on board and management changes and meeting resolutions, not on detailed financial data or full report content. Therefore, this document fits best under the category of Board/Management Information (MANG). The document length is 2775 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report.
2024-10-29 Chinese
独立董事候选人声明与承诺（胡左浩）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate (胡左浩) for Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the candidate's qualifications, independence, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or report attachments. The content is related to board/management information, specifically about a director candidate's declaration and commitment. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on director candidacy, not a report or announcement of voting results.
2024-10-29 Chinese
独立董事候选人声明与承诺（邵荣光）
Board/Management Information Classification · 95% confidence The document is a statement and commitment by an independent director candidate (邵荣光) for Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the candidate's qualifications, independence criteria, and legal compliance related to the role of an independent director. There are no financial statements, earnings data, or report attachments. The document is a regulatory announcement related to board/management information, specifically about a director candidate's declaration and commitment. It does not fit into categories like Annual Report, Earnings Release, or Proxy Solicitation. The best fitting category is Board/Management Information (MANG). The document length is short and focused on management nomination and compliance, confirming this classification with high confidence.
2024-10-29 Chinese
第三届监事会第二十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes the approval of the 2024 third quarter report and the nomination of candidates for the next Supervisory Board. The document references the 2024 third quarter report but does not contain the report itself or detailed financial data. It also mentions that the full third quarter report is disclosed on the Beijing Stock Exchange website. The document is primarily a meeting resolution and announcement of decisions rather than the actual quarterly report. Given the short length (1679 characters) and the nature of the content, this fits best as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Management Report (MDA).
2024-10-29 Chinese
独立董事候选人声明与承诺（钱爱民）
Board/Management Information Classification · 95% confidence The document is a statement and commitment by an independent director candidate (钱爱民) for Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the candidate's qualifications, independence criteria, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or report attachments. The document is a regulatory announcement related to board/management information, specifically about a director candidate's declaration and commitment. It does not fit into categories like Annual Report, Earnings Release, or Proxy Solicitation. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on management nomination and compliance, confirming this classification with high confidence.
2024-10-29 Chinese
2024年第一次职工代表大会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution from the company's 2024 first employee representative meeting, including election results for a supervisory board member. It contains no financial statements or detailed financial data, nor is it a report or presentation. It is a corporate governance-related announcement about board/supervisory committee composition changes. It is not an AGM information document, nor a full annual or interim report. The content fits best under Board/Management Information (MANG) as it announces changes in the supervisory board membership following an internal election. The document length is short and focused on governance matters, not financial results or regulatory filings.
2024-10-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.